Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05422118
Other study ID # Soh-Med-22-06-07
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 10, 2022
Est. completion date December 2022

Study information

Verified date August 2022
Source Sohag University
Contact Alaa S Mohamed, resident
Phone 01159603636
Email alaasabr@med.sohag.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Spontaneous bacterial peritonitis (SBP) is an infection of the ascitic fluid in patients with liver cirrhosis and portal hypertension. There is no obvious surgical cause as perforation or intraabdominal inflammatory focus as abscess. Up to 30% of the ascitic patients will develop SBP. SBP is attributed to immune dysfunction, bacterial translocation, circulatory dysfunction and inflammatory status. SBP is diagnosed by ascitic fluid analysis . SBP was defined as polymorphonuclear leucocyte count (PMN) >250/mm3 in ascitic fluid, . Not all cases are associated with positive ascitic fluid cultures. There are variants of ascitic fluid infections as culture-negative neutrocytic ascites, monomicrobial non-neutrocytic bacterascites, polymicrobial bacterascites and secondary bacterial peritonitis. The advent of the SBP carries a poor prognosis where the hospital mortality ranged from 10 to 50%. As a consequence, any patient with SBP should be assessed for liver transplantation. Immediate treatment with antibiotics and IV albumin should be initiated. Studies were conducted on alternatives of the ascitic PMN count as high sensitivity C-reactive protein (hsCRP), serum procalcitonin, urinary lipocalin, ascitic lactoferrin, homocysteine and fecal or ascitic calprotectin. The gold standard test for SBP is ascitic fluid analysis with measurement of the PMN. It is useful for the diagnosis and monitoring of treatment. The culture of the ascitic fluid may be positive if was done correctly . There is a variant of SBP that is called culture-negative neutrocytic ascites. It is characterized by elevated ascitic fluid PMN but the culture is negative. It is managed exactly as classic SBP. Such cases would be missed if cultures were not done The manual PMN counting is time consuming, laborious and required some experience to avoid intra- and inter-observer variability. So, a simple rapid bedside test would be useful clinically. Calprotectin is acute-phase inflammatory protein that is released from the PMN. Calprotectin has anti-proliferative and antimicrobial properties. Calprotectin is used clinically widespread in the diagnosis and monitoring treatment of inflammatory bowel disease .


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - The patients were divided into two groups: 1. Non-SBP group: it included 25 patients with cirrhotic ascites without clinical or laboratory evidence of SBP. 2. SBP group: it included 25 patients with cirrhotic ascites with SBP. They were diagnosed by positive ascitic fluid bacterial culture, an increase in PMNLs count in ascites (>250 cells/mm3) and without any intra-abdominal source of infection. Exclusion Criteria: - (1) Cirrhotic patients with and without SBP receiving antibiotics in last 1 week. (2) Recent abdominal surgery (<3 months). (3) abdominal malignancy [hepatocellular carcinoma (HCC), colorectal carcinoma, gastric carcinoma, pancreatic carcinoma, cholangiocarcinoma]. (4) Intra-abdominal infected lesions, such as abscess, appendicitis, cholecystitis, and pancreatitis. (5) History of inflammatory bowel disease (Crohn's disease, ulcerative colitis). (6) patients with heart failure (HF), hematological, and autoimmune disorders were excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
ascitic fluid calprotectin
ascitic fluid calprotectin

Locations

Country Name City State
Egypt Sohag University Hospital Sohag

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

References & Publications (4)

Bernardi M. Spontaneous bacterial peritonitis: from pathophysiology to prevention. Intern Emerg Med. 2010 Oct;5 Suppl 1:S37-44. doi: 10.1007/s11739-010-0446-x. Review. — View Citation

European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010 Sep;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004. Epub 2010 Jun 1. Review. — View Citation

Marciano S, Díaz JM, Dirchwolf M, Gadano A. Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies. Hepat Med. 2019 Jan 14;11:13-22. doi: 10.2147/HMER.S164250. eCollection 2019. Review. — View Citation

Xiol X, Castellví JM, Guardiola J, Sesé E, Castellote J, Perelló A, Cervantes X, Iborra MJ. Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology. 1996 Apr;23(4):719-23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 1-CBC WBCs count and differential,RBCs count,HB,mcv,Mch,Mchc,platelete count 6 months
Primary 2-liver function test AlT,ASt,Albumin,total protein,bilirubin 6 months
Primary 3-Renal function test serum create and urea 6 months
Primary 4-Ascitic fluid analysis(physical,chemical,microscopic) physical(colour,aspect) chemical(protien,glucose) microscopical(wbcs total and differential,Rbcs),bacterial culture 6 months
Primary Ascitic Fluid calprotectin ascitic fluid calprotectin by ELISA 6 months
Primary INR international normalization time 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06026267 - Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis N/A
Withdrawn NCT02552862 - Study of the Effect of Adjunctive Vivomixx® in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP) Phase 3
Completed NCT02528097 - A Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis N/A
Completed NCT01193426 - Diagnostic of Spontaneous Bacterial Peritonitis
Completed NCT00359853 - Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis Phase 4
Active, not recruiting NCT04159870 - Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis Phase 3
Completed NCT04153604 - Doxycycline for the Prevention of Spontaneous Bacterial Peritonitis
Completed NCT06234046 - Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin Phase 3
Recruiting NCT01598870 - Diagnosis of Spontaneous Bacterial Peritonitis N/A
Recruiting NCT00761098 - Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Phase 4
Completed NCT05401721 - Serum Copeptin in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
Completed NCT02468089 - To Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis N/A
Not yet recruiting NCT04746937 - Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis Phase 3
Recruiting NCT02759497 - Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis N/A
Completed NCT02608658 - Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites N/A
Completed NCT02388035 - Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis N/A
Completed NCT03163745 - Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis
Completed NCT04273373 - Low Dose Albumin Versus Standard Dose Albumin in High Risk Spontaneous Bacterial Peritonitis. N/A
Active, not recruiting NCT04395365 - Primary Antibiotic Prophylaxis Using Co-trimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis Phase 3
Terminated NCT00570960 - Clinical, Inflammatory, and Economic Impact of Dextran 70 in Treating Spontaneous Bacterial Peritonitis Phase 4